Abstract

A growing number of studies of science, technology and innovation policy are taking argumentative practices as a privileged unit of analysis. Underpinning this development is the observation that, empirically, science, technology and innovation policies are often formulated and implemented through bargaining between competing coalitions of actors. I put this claim to practice by examining the recent emergence of translational research and translational medicine as central priority in the biomedical policy of the USA and Germany. Drawing on document analysis and semi-structured interviews with thirty-five biomedical researchers and policy-makers, I find that a specific group of actors, clinician-scientists, have successfully built a coalition concerned with increasing institutional support for their profession by claiming their role as privileged leaders of translational research initiatives. In doing so, they have simultaneously shaped the research agendas and institutional practices associated with translational research.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.